Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

MYC-Alarmin Axis As a Novel Oncogenic Driver in a Subgroup of Triple Negative Myeloproliferative Neoplasms

Blood (2023) 142 (Supplement 1): 994.

https://doi.org/10.1182/blood-2023-174383

Published: 2023

Journal Articles

High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients

Virginia Olivia Volpe, Nicole D. Vincelette, Onyee Chan, Chetasi Talati, Kendra Sweet, Andrew T. Kuykendall, Constantine Logothetis, Rami S. Komrokji, Gregoire Calon, Nathan P. Horvat, David A. Sallman, Eric Padron, Ling Zhang, Seongseok Yun

Blood (2021) 138 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2021-147030

Published: 2021

Journal Articles

C-MYC Augments the Proliferation and Survival of Hematopoietic Stem Cells and Multipotent Progenitors to Drive Myeloproliferative Neoplasms

Nicole D. Vincelette, Jungwon Moon, Andrew T. Kuykendall, Ling Zhang, Rami S. Komrokji, Daniel Murphy, John L. Cleveland, Seongseok Yun

Blood (2021) 138 (Supplement 1): 28.

https://doi.org/10.1182/blood-2021-146399

Published: 2021

Journal Articles

Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137209

Published: 2020

Journal Articles

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Seongseok Yun, MDPhD, David Gajzer, MD, Najla Al Ali, M.Sc, Nicole D. Vincelette, PhD, Pukhraz Basra, MBBS, Chetasi Talati, MD, Andrew T. Kuykendall, MD, Eric Padron, MD, Kendra Sweet, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137116

Published: 2020

Journal Articles

Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant

Seongseok Yun, MDPhD, Onyee Chan, MD, Daniel Kerr, MDPhD, Nicole D. Vincelette, PhD, Afshan Idrees, MD MPH, Qianxing Mo, PhD, Kendra Sweet, MD, Jeffrey E. Lancet, MD, Mohamed A kharfan-Dabaja, MDMBA, Ling Zhang, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-133391

Published: 2020

Journal Articles

Prognostic Impact of MYC Oncoprotein Expression on Survival Outcome in Secondary AML Patients

Seongseok Yun, MD PhD, Rohit Sharma, MD, David A Sallman, MD, Nicole D. Vincelette, PhD, Kendra L. Sweet, MD, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Lynn C. Moscinski, MD, John Cleveland, PhD, Alan F. List, MD, Ling Zhang, MD

Blood (2018) 132 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2018-99-120048

Published: 2018

Journal Articles

Genomic-DNA Exposed By Somatic Gene Mutations Engages the cGAS/STING Axis to License the NLRP3 Inflammasome in Myelodysplastic Syndromes

Amy F McLemore, M.S., Kathy L McGraw, PhD, Hsin-An Hou, MD PhD, Grace A Ward, BS, Alexis H Onimus, BS, Nicole D. Vincelette, PhD, Matthew A. Rodrigues, PhD, Neelkamal Chaudhary, PhD, Ling Zhang, MD, Benjamin S. Meyer, Erika A Eksioglu, PhD MS, Sheng Wei, MD, Alan F. List, MD

Blood (2018) 132 (Supplement 1): 3075.

https://doi.org/10.1182/blood-2018-99-116929

Published: 2018

Journal Articles

Oxidized Mitochondrial DNA Is a Catalyst and Biomarker of Pyroptotic Cell Death in Myelodysplastic Syndromes

Grace A Ward, BS, Kathy L McGraw, PhD, Amy F McLemore, M.S., Farnoosh Abbas-Aghababazadeh, PhD, Hsin-An Hou, MD PhD, Thu Le Trinh, PhD, Nicole D. Vincelette, PhD, Benjamin S. Meyer, Alexis H Onimus, BS, Alexandra Calescibetta, Erika A Eksioglu, PhD MS, Sheng Wei, MD, Alan F. List, MD

Blood (2018) 132 (Supplement 1): 3076.

https://doi.org/10.1182/blood-2018-99-118493

Published: 2018

Journal Articles

Prognostic Impact of Concurrent BCR/ABL1 Gene Rearrangement on Survival Outcome in Ph-like B-ALL Patients

Seongseok Yun, MD PhD, Nicole D. Vincelette, PhD, Jeffrey E. Lancet, MD, Julio C. Chavez, MD, Bijal D. Shah, MD, Ling Zhang, MD

Blood (2017) 130 (Supplement 1): 5114.

https://doi.org/10.1182/blood.V130.Suppl_1.5114.5114

Published: 2017

Journal Articles

Risk of Atrial Fibrillation and Bleeding Diathesis Associated with Ibrutinib Treatment: A Pooled-Analysis of Four Randomized Trials

Seongseok Yun, MD PhD, Nicole D. Vincelette, PhD, Utkarsh Acharya, DO, Ivo Abraham, PhD

Blood (2016) 128 (22): 5584.

https://doi.org/10.1182/blood.V128.22.5584.5584

Published: 2016

Journal Articles

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Seongseok Yun, Nicole D. Vincelette, Katherine L. B. Knorr, Luciana L. Almada, Paula A. Schneider, Kevin L. Peterson, Karen S. Flatten, Haiming Dai, Keith W. Pratz, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Andrea E. Wahner Hendrickson, Martin E. Fernandez-Zapico, Scott H. Kaufmann

Blood (2016) 127 (22): 2711–2722.

https://doi.org/10.1182/blood-2015-02-629485

Published: 2016

Includes: Supplemental data

Journal Articles

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Seongseok Yun, MD PhD, Nicole D. Vincelette, Katherine L. B. Knorr, PhD, Luciana L. Almada, PhD, Paula A. Schneider, Kevin L. Peterson, PhD, Karen S. Flatten, Allan D. Hess, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Martin E. Fernandez-Zapico, MD, Scott H. Kaufmann, MD PhD

Blood (2015) 126 (23): 3705.

https://doi.org/10.1182/blood.V126.23.3705.3705

Published: 2015

NARROW

MYC-Alarmin Axis As a Novel Oncogenic Driver in a Subgroup of Triple Negative Myeloproliferative Neoplasms

High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients

C-MYC Augments the Proliferation and Survival of Hematopoietic Stem Cells and Multipotent Progenitors to Drive Myeloproliferative Neoplasms

Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant

Prognostic Impact of MYC Oncoprotein Expression on Survival Outcome in Secondary AML Patients

Genomic-DNA Exposed By Somatic Gene Mutations Engages the cGAS/STING Axis to License the NLRP3 Inflammasome in Myelodysplastic Syndromes

Oxidized Mitochondrial DNA Is a Catalyst and Biomarker of Pyroptotic Cell Death in Myelodysplastic Syndromes

Prognostic Impact of Concurrent BCR/ABL1 Gene Rearrangement on Survival Outcome in Ph-like B-ALL Patients

Risk of Atrial Fibrillation and Bleeding Diathesis Associated with Ibrutinib Treatment: A Pooled-Analysis of Four Randomized Trials

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only